Old Web
English
Sign In
Acemap
>
authorDetail
>
Barry Press
Barry Press
Ontario Institute for Cancer Research
Pharmacology
Proteasome inhibitor
Medicine
Pharmacokinetics
In vivo
4
Papers
102
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing
2015
Cell Death and Disease
Zhuozhi Wang
Patric Dove
Xiaosong Wang
Aisha Shamas-Din
Ziqin Li
Adrian Nachman
Yeon Ji Oh
Rose Hurren
Amy M. Ruschak
Shane Climie
Barry Press
Courtney Griffin
Elijus Undzys
Ahmed Aman
Rima Al-awar
Lewis E. Kay
David O'Neill
Suzanne Trudel
Malik Slassi
Aaron D. Schimmer
Show All
Source
Cite
Save
Citations (3)
FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo
2013
Blood
Peter Dove
Xiaoming Wang
Carolyn A. Goard
Zhihua Li
Alex Nachman
Yoonsun Jenny Oh
Rose Hurren
Amy M. Ruschak
Shane Climie
David O'Neill
Barry Press
Carly Griffin
Elijus Undzys
Ahmed Aman
Rima Al-awar
Lewis E. Kay
Suzanne Trudel
Malik Slassi
Aaron D. Schimmer
Show All
Source
Cite
Save
Citations (0)
A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases
2012
Journal of Controlled Release
Mark J. Ernsting
Mami Murakami
Elijus Undzys
Ahmed Aman
Barry Press
Shyh-Dar Li
Show All
Source
Cite
Save
Citations (79)
Optimization of the Caco-2 permeability assay to screen drug compounds for intestinal absorption and efflux.
2011
Methods of Molecular Biology
Barry Press
Show All
Source
Cite
Save
Citations (20)
1